Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 7/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972890 | 0.81 | KMT2A (0.65) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL27300181 | 0.79 | KMT2A (0.63) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL8968526 | 0.78 | IDO1 (0.48) | KMT2ACA2CA1CA9PRSS1 | |
| SCHEMBL16207220 | 0.78 | CA2 (0.53) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL14422308 | 0.77 | KMT2A (0.61) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL7999646 | 0.77 | KMT2A (0.61) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL6114729 | 0.77 | KMT2A (0.61) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL9344000 | 0.77 | KMT2A (0.61) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL7307521 | 0.77 | KMT2A (0.61) | KMT2ACA2CA1CA9CA5A | |
| SCHEMBL4594148 | 0.77 | KMT2A (0.61) | KMT2ACA2CA1CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | claimed |
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-07-14 | — | — | US | claimed |
| WO-2021195465-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | MAGNANI JOHN L (US) | 2021-09-30 | — | — | WO | claimed |
| WO-2020219419-A1 | MULTIMERIC PAN–SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| US-20200171005-A9 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker | GLYCOMIMETICS, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-20180369205-A1 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker | GLYCOMIMETICS, INC. (US) | 2018-12-27 | — | — | US | claimed |
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | claimed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | claimed |
| US-8530448-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2013-09-10 | — | — | US | claimed |
| EP-1934236-B1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2012-11-21 | — | — | EP | claimed |
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | GLYCOMIMETICS, INC (US) | 2009-02-05 | — | — | US | claimed |
| EP-1934236-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GlycoMimetics, Inc. (US) | 2008-06-25 | — | — | EP | claimed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | claimed |
| WO-2007028050-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2006127906-A1 | HETEROBIFUNCTIONAL COMPOUNDS FOR SELECTIN INHIBITION | GLYCOMIMETICS, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060194745-A1 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2006-08-31 | — | — | US | claimed |
| EP-1685145-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GlycoMimetics, Inc. (US) | 2006-08-02 | — | — | EP | claimed |
| US-7060685-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2006-06-13 | — | — | US | claimed |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | GLYCOMIMETICS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| WO-2005054264-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GLYCOMIMETICS, INC. (US) | 2005-06-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | SELE, SELL, BSG | KMT2A 2610/4885CA2 2351/4885CA1 1454/4885 |
| US-20060194745-A1 | Compounds and methods for inhibiting selectin-mediated function | SELE, SELL, SELP | KMT2A 2401/4885CA2 2139/4885CA1 697/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | KMT2A 3600/4885CA2 1710/4885CA1 671/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | KMT2A 2335/4885CA2 2193/4885CA1 980/4885 |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | SELE, SELP, SELPLG | KMT2A 2775/4885CA2 2843/4885CA1 1958/4885 |
| US-20200171005-A9 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker | SELE, SELP, SELPLG | KMT2A 2355/4885CA2 3118/4885CA1 1451/4885 |
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | SELE, SELP, BSG | KMT2A 2324/4885CA2 2559/4885CA1 1307/4885 |
| US-20180369205-A1 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker | SELE, SELP, SELPLG | KMT2A 2355/4885CA2 3118/4885CA1 1451/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | KMT2A 3939/4885CA2 3911/4885CA1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.